# Mesa Verde Venture Partners

> Mesa Verde Venture Partners is a VC fund backing Biotechnology. See 19 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Diego, United States
- Total investments: 19
- Last investment: Apr 2026
- Lead investor: 11%
- Last updated: Aug 2026
- Website: http://www.mesaverdevp.com

Mesa Verde Venture Partners is a VC fund in San Diego focused on Biotechnology and Health Care. Mesa Verde Venture Partners focuses on investing in a diversified portfolio of early-stage biotechnology and medical technology companies. Its areas of focus include drug discovery/tools, medical devices and diagnostics, and healthcare information technology. The company was founded in 2006 and headquartered in San Diego, California.

## Contacts

5 contacts available for Mesa Verde Venture Partners. Shizune tracks 1 team members at Mesa Verde Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mesa-verde-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 63% |
| Health Care | 8 | 42% |
| Medical | 6 | 32% |
| Therapeutics | 6 | 32% |
| Pharmaceutical | 4 | 21% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 37% |
| Series A | 3 | 16% |
| Series C | 2 | 11% |
| Venture - Series Unknown | 2 | 11% |
| Seed | 1 | 5% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Carey J. Ng | Managing Director | 1 | https://shizune.co/investors/profile/carey-j-ng |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Acurion | Acurion develops AI-driven diagnostic solutions that extract actionable genomic biomarker insights from standard pathology images to inform oncology treatment decisions. The company’s core product, OncoGaze™, analyzes digitized tumor biopsy slides to identify clinically relevant molecular features such as homologous recombination deficiency thatguide therapy selection more rapidly than conventional genomic testing. Acurion’s platform integrates into existing clinical workflows to support earlier precision medicine decisions for cancer care and is being expanded to detect additional biomarkers across various tumor types. The company collaborates with research and clinical partners to advance applications of its machine learning technology in oncology and related areas. | $4.3M | Seed | Apr 02, 2026 |  |
| MARAbio | MARAbio is a biotech firm that works to detect and prevent severe forms of Autism. | $19.1M | Series A | Oct 07, 2024 |  |
| Zavante Therapeutics | Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. |  | Venture - Series Unknown | Jan 01, 2021 |  |
| Immusoft | Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft.Thetechnology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years.It was founded in 2009 and is headquartered in Seattle, Washington. | $4.5M | Venture - Series Unknown | Sep 25, 2020 |  |
| VelosBio | VelosBio is an operator of a clinical-stage biopharmaceutical company intended to develop novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. The company's ROR1-directed therapeutics is a cell-surface protein that is expressed on many hematologic and solid tumors but is absent from normal tissues,making it an attractive tumor-specific therapeutic target and has demonstrated positive preclinical results in tumor models, enabling institutions to get novel targeted therapies for use as monotherapy or in combination across a broad range of cancers.It was founded in 2017 and headquartered in San Diego, California. | $137M | Series B | Jul 08, 2020 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $15M | Series C | May 22, 2020 |  |
| Paradigm Diagnostics | Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of thepatient’s tumor; thus, personalizing each patient’s course of treatment. | $15M | Series B | May 21, 2019 |  |
| Immusoft | Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft.Thetechnology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years.It was founded in 2009 and is headquartered in Seattle, Washington. | $20M | Series B | Jan 03, 2019 |  |
| Paradigm Diagnostics | Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of thepatient’s tumor; thus, personalizing each patient’s course of treatment. | $8.9M | Series B | Aug 02, 2018 |  |
| Biscayne Pharmaceuticals | Biscayne Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops therapies based on growth hormone-releasing hormone (GHRH) analogs. The compounds include GHRH antagonists in development for the treatment of cancer, including castrate-resistant prostate cancer, and GHRH agonists for the repair of cardiac damage in heart diseasepatients. The company was incorporated in 2012 and is headquartered in Miami, Florida. | $3M | Series B | Jan 31, 2017 |  |

10 of 19 investments shown.

## Co-investors
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 3 deals together
- [Care Capital](https://shizune.co/investors/profile/care-capital) — VC Fund, 3 deals together
- [Sanderling Ventures](https://shizune.co/investors/profile/sanderling-ventures) — VC Fund, 3 deals together
- [Breakout Ventures](https://shizune.co/investors/profile/breakoutventures) — VC Fund, 2 deals together
- [Cottonwood Technology Fund](https://shizune.co/investors/profile/cottonwood-technology-fund) — VC Fund, 2 deals together
- [EPIC Ventures](https://shizune.co/investors/profile/epic-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Mesa Verde Venture Partners invest in?

Mesa Verde Venture Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Mesa Verde Venture Partners?

Public channels for Mesa Verde Venture Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Mesa Verde Venture Partners?

The team at Mesa Verde Venture Partners includes Carey J. Ng (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co